AEGiS-FDA: Approval of generic stavudine for oral solution, 1 mg/mL Food and Drug AdministrationImportant note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Click here to return to FDA main menu
DonateNow


Approval of generic stavudine for oral solution, 1 mg/mL

Food and Drug Administration - March 23, 2009

On March 20, 2009, the Food and Drug Administration (FDA) approved a generic formulation of stavudine for oral solution, 1 mg/mL. Stavudine is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) indicated for used in combination with other antiretroviral agents in the treatment of HIV infection. This child-friendly product, manufactured by Cipla, Limited, of Mumbai, India, is indicated for use in pediatric patients with HIV from birth through adolescence.

A tentative approval was granted on October 29, 2007 for this product. At that time, existing patent protections prevented full approval for marketing in the United States.

Because patent protection has since expired for the originator product, Zerit(R) for oral solution, 1 mg/mL, made by Bristol Myers Squibb, the generic product qualifies for approval. Effective patent dates for FDA approved drugs can be found in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the "Orange Book <http://www.fda.gov/cder/ob/docs/querytn.htm>."

Richard Klein

Office of Special Health Issues

Food and Drug Administration

Kimberly Struble

Division of Antiviral Drug Products

Food and Drug Administration
090323
FD090305

SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .